ASE · Biotechnology

Lineage Cell Therapeutics, Inc. (LCTX) Stock

$0.99 -3.50% ASE: LCTX Healthcare

Valuation

MetricValue
Price$0.99
Market Cap$247.80M
P/E Ratio-6.61
P/B Ratio3.80
P/S Ratio17.67
EPS (TTM)$-0.08
52-Week High$2.09
52-Week Low$0.88
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-71.14%
ROA-30.37%
ROCE-27.34%
Gross Margin-140.00%
Operating Margin-146.67%
Net Margin-246.58%
Debt/Equity0.04
Current Ratio5.36

Annual Financials (USD)

Metric20212022202320242025
Revenue$4.0M$15.0M$9.0M$9.0M$15.0M
Operating Profit$-49.0M$-23.0M$-25.0M$-21.0M$-22.0M
Net Profit$-43.0M$-26.0M$-21.0M$-19.0M$-64.0M
EPS$-0.26$-0.15$-0.12$-0.09$-0.28
Op Margin-1263.1%-153.2%-276.5%-226.1%-149.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$175.0M$124.0M$101.0M$113.0M$113.0M
Total Liabilities$84.0M$52.0M$39.0M$36.0M$69.0M
Cash$56.0M$11.0M$35.0M$46.0M$41.0M
Borrowings$3.0M$4.0M$3.0M$3.0M$2.0M

Latest News

Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject’ Cell Therapy Plan MarketBeat · Jul 14, 2026 Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease Business Wire · Jul 13, 2026 Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit Business Wire · Jul 6, 2026 Lineage Cell Therapeutics (LCTX) Stock Faces Mixed Analyst Target Changes After Fresh Coverage Simply Wall St. · Jun 18, 2026 How The Lineage Cell Therapeutics (LCTX) Story Is Shifting With New Data And Analyst Targets Simply Wall St. · Jun 4, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-24.0M$1.0M$-29.0M$-23.0M$-19.0M
Investing Cash Flow$9.0M$-47.0M$46.0M$-3.0M$-14.0M
Financing Cash Flow$6.0M$2.0M$0$0$0
Net Cash Flow$23.0M$-44.0M$24.0M$10.0M$-5.0M
Free Cash Flow$-24.0M$1.0M$-29.0M$-24.0M$-19.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.17
EV / EBITDA-5.35
FCF Yield-10.35%
Quick Ratio6.61
Interest Coverage0.00
Return 1Y-0.93%
Return 3Y-23.57%
Return 5Y-54.81%

Ownership

Insiders Held4.93%
Institutions Held47.46%
Institutions Float Held49.92%
Institutional HolderSharesReport Date
Broadwood Capital, Inc.49,560,9922026-03-31
Vanguard Capital Management LLC8,318,6852026-03-31
Defender Capital, LLC6,598,8992026-06-30
Millennium Management Llc5,561,3742026-03-31
Raffles Associates Lp5,362,7882026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. is led by CEO Brian Culley, employs 70 people, headquartered in US, publicly traded since 1992.

Lineage Cell Therapeutics, Inc. (LCTX) stock trades at $0.99 with a market capitalization of $247.80M. The stock is valued at a price-to-earnings (P/E) ratio of -6.61, price-to-book of 3.80, price-to-sales of 17.67. Over the past 52 weeks the stock has ranged between $0.88 and $2.09, and currently trades 52.6% below its 52-week high.

On profitability, Lineage Cell Therapeutics, Inc. generates a return on equity (ROE) of -71.14%, return on capital employed of -27.34%, an operating margin of -146.67%, a net profit margin of -246.58%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides